Lu Genmin, Broze George J, Krishnaswamy Sriram
Joseph Stokes Research Institute, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA.
J Biol Chem. 2004 Apr 23;279(17):17241-9. doi: 10.1074/jbc.M312827200. Epub 2004 Feb 12.
The activation of factor X by VIIa/TF and the Xa-dependent inhibition of the enzyme complex by tissue factor pathway inhibitor (TFPI) are considered primary steps in the initiation of coagulation. IX activation by VIIa/TF is considered to contribute catalyst necessary for further Xa production in the ensuing amplification phase. We have investigated Xa and IXabeta production by VIIa-TF in a system reconstituted with both X and IX and the principal physiologic inhibitors of this pathway TFPI and antithrombin III (AT). Kinetic studies without inhibitors established that IX and X functioned as competitive alternate substrates for VIIa/TF with similar kinetic constants. When both IX and X were present, TFPI significantly inhibited the extent of formation of either IXabeta or Xa. In contrast, AT rapidly depleted active Xa with a small effect on IXabeta formation. When both AT and TFPI were present, active IXabeta formation significantly exceeded the formation of active Xa regardless of the VIIa/TF concentration. These findings could be quantitatively accounted for by a model encompassing the kinetics of the individual activation and inhibition steps. Active Xa formation by this pathway is regulated in a principal way by its rapid inactivation by AT. In contrast, the Xa-dependent inhibitory reactions of TFPI play a primary role in limiting zymogen consumption and the formation of active IXabeta. These regulatory phenomena yield active IXabeta as a major rather than secondary product of VIIa/TF. Our findings raise the possibility that IXabeta produced by the extrinsic pathway, and its ability to function within the intrinsic Xase complex to activate X may play a significant role in producing Xa necessary for both the initiation and sustained phases of the procoagulant response following vascular damage.
VIIa/TF对因子X的激活以及组织因子途径抑制剂(TFPI)对该酶复合物的Xa依赖性抑制被认为是凝血启动的主要步骤。VIIa/TF对IX的激活被认为有助于在随后的放大阶段产生进一步的Xa所需的催化剂。我们在一个用X和IX以及该途径的主要生理抑制剂TFPI和抗凝血酶III(AT)重构的系统中研究了VIIa-TF产生Xa和IXabeta的情况。没有抑制剂的动力学研究表明,IX和X作为VIIa/TF的竞争性替代底物发挥作用,具有相似的动力学常数。当IX和X都存在时,TFPI显著抑制IXabeta或Xa的形成程度。相比之下,AT迅速消耗活性Xa,对IXabeta的形成影响较小。当AT和TFPI都存在时,无论VIIa/TF浓度如何,活性IXabeta的形成都显著超过活性Xa的形成。这些发现可以通过一个包含各个激活和抑制步骤动力学的模型进行定量解释。该途径产生的活性Xa主要通过其被AT迅速灭活来调节。相比之下,TFPI的Xa依赖性抑制反应在限制酶原消耗和活性IXabeta的形成中起主要作用。这些调节现象使活性IXabeta成为VIIa/TF的主要而非次要产物。我们的发现提出了一种可能性,即外源性途径产生的IXabeta及其在内在Xase复合物中激活X的能力可能在产生血管损伤后促凝反应起始和持续阶段所需的Xa中发挥重要作用。